| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Organ Transplantation | 59 | 2023 | 1177 | 8.530 |
Why?
|
| Transplantation, Heterologous | 66 | 2024 | 2394 | 7.600 |
Why?
|
| Immunocompromised Host | 31 | 2023 | 863 | 4.070 |
Why?
|
| Cytomegalovirus Infections | 29 | 2024 | 839 | 3.130 |
Why?
|
| Cytomegalovirus | 19 | 2024 | 754 | 2.700 |
Why?
|
| Tissue Donors | 27 | 2024 | 2389 | 2.650 |
Why?
|
| Pneumonia, Pneumocystis | 20 | 2023 | 242 | 2.590 |
Why?
|
| Kidney Transplantation | 37 | 2024 | 4300 | 2.460 |
Why?
|
| Transplantation | 14 | 2013 | 221 | 2.370 |
Why?
|
| Communicable Diseases | 14 | 2024 | 873 | 2.340 |
Why?
|
| Virus Diseases | 10 | 2023 | 723 | 2.160 |
Why?
|
| Opportunistic Infections | 10 | 2014 | 375 | 2.140 |
Why?
|
| Tissue and Organ Procurement | 12 | 2018 | 986 | 2.070 |
Why?
|
| Zoonoses | 13 | 2024 | 180 | 1.970 |
Why?
|
| Swine | 60 | 2024 | 5994 | 1.910 |
Why?
|
| Pneumocystis carinii | 4 | 2023 | 72 | 1.850 |
Why?
|
| Retroviridae Infections | 8 | 2018 | 148 | 1.820 |
Why?
|
| Endogenous Retroviruses | 11 | 2020 | 112 | 1.780 |
Why?
|
| Donor Selection | 5 | 2014 | 240 | 1.690 |
Why?
|
| Liver Transplantation | 20 | 2020 | 2400 | 1.440 |
Why?
|
| Immunosuppressive Agents | 23 | 2023 | 4209 | 1.400 |
Why?
|
| Graft Rejection | 26 | 2021 | 4505 | 1.340 |
Why?
|
| Transplants | 6 | 2016 | 208 | 1.340 |
Why?
|
| Antifungal Agents | 17 | 2016 | 759 | 1.310 |
Why?
|
| Cryptococcosis | 5 | 2014 | 103 | 1.270 |
Why?
|
| Pneumocystis Infections | 5 | 2019 | 10 | 1.260 |
Why?
|
| Disease Transmission, Infectious | 9 | 2017 | 562 | 1.190 |
Why?
|
| Hepatitis C | 8 | 2022 | 1593 | 1.110 |
Why?
|
| Pneumocystis | 14 | 2001 | 55 | 1.110 |
Why?
|
| Mycoses | 8 | 2014 | 386 | 1.060 |
Why?
|
| Ganciclovir | 10 | 2007 | 256 | 0.970 |
Why?
|
| Infection Control | 4 | 2019 | 985 | 0.940 |
Why?
|
| Central Nervous System Infections | 2 | 2014 | 61 | 0.890 |
Why?
|
| Papio | 23 | 2018 | 672 | 0.880 |
Why?
|
| Herpesviridae Infections | 4 | 2013 | 269 | 0.850 |
Why?
|
| Transplantation Immunology | 10 | 2013 | 538 | 0.780 |
Why?
|
| Antiviral Agents | 18 | 2020 | 3064 | 0.750 |
Why?
|
| Retroviridae | 5 | 2010 | 849 | 0.730 |
Why?
|
| Parasites | 1 | 2023 | 160 | 0.730 |
Why?
|
| Graft Survival | 14 | 2020 | 3900 | 0.720 |
Why?
|
| Swine, Miniature | 15 | 2012 | 965 | 0.720 |
Why?
|
| Heart Transplantation | 15 | 2024 | 3300 | 0.700 |
Why?
|
| Tissue Transplantation | 2 | 2012 | 128 | 0.690 |
Why?
|
| DNA, Viral | 10 | 2018 | 2205 | 0.680 |
Why?
|
| Nucleic Acids | 1 | 2022 | 189 | 0.670 |
Why?
|
| Transplantation, Homologous | 11 | 2016 | 4834 | 0.650 |
Why?
|
| Humans | 208 | 2024 | 768393 | 0.620 |
Why?
|
| Anti-Infective Agents | 6 | 2012 | 985 | 0.620 |
Why?
|
| Epstein-Barr Virus Infections | 4 | 2014 | 617 | 0.610 |
Why?
|
| Postoperative Complications | 19 | 2019 | 15881 | 0.610 |
Why?
|
| Serologic Tests | 2 | 2017 | 383 | 0.610 |
Why?
|
| Varicellovirus | 2 | 2008 | 7 | 0.600 |
Why?
|
| Polyomavirus Infections | 4 | 2007 | 192 | 0.580 |
Why?
|
| Coronavirus | 1 | 2020 | 156 | 0.580 |
Why?
|
| Pneumonia, Viral | 5 | 2020 | 3241 | 0.570 |
Why?
|
| BK Virus | 3 | 2003 | 120 | 0.570 |
Why?
|
| Viral Load | 5 | 2020 | 3398 | 0.550 |
Why?
|
| Advisory Committees | 2 | 2021 | 797 | 0.540 |
Why?
|
| Animals | 106 | 2024 | 169337 | 0.540 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 2 | 2010 | 450 | 0.520 |
Why?
|
| Coronavirus Infections | 4 | 2020 | 3118 | 0.510 |
Why?
|
| Immune System Diseases | 3 | 2015 | 253 | 0.510 |
Why?
|
| Laboratories | 2 | 2014 | 463 | 0.500 |
Why?
|
| Tumor Virus Infections | 3 | 2003 | 438 | 0.490 |
Why?
|
| Gammaherpesvirinae | 3 | 2005 | 27 | 0.490 |
Why?
|
| Virus Replication | 10 | 2013 | 2458 | 0.480 |
Why?
|
| Invasive Pulmonary Aspergillosis | 1 | 2014 | 18 | 0.480 |
Why?
|
| AIDS-Related Opportunistic Infections | 4 | 2009 | 664 | 0.470 |
Why?
|
| Antigens, Fungal | 1 | 2014 | 69 | 0.470 |
Why?
|
| Mannans | 1 | 2014 | 58 | 0.470 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2014 | 61 | 0.460 |
Why?
|
| Immunity, Innate | 5 | 2024 | 3078 | 0.450 |
Why?
|
| Kidney | 11 | 2024 | 7064 | 0.440 |
Why?
|
| Adaptive Immunity | 2 | 2016 | 731 | 0.430 |
Why?
|
| Galactosyltransferases | 7 | 2014 | 284 | 0.420 |
Why?
|
| Vancomycin Resistance | 2 | 2003 | 125 | 0.420 |
Why?
|
| Respiratory Tract Infections | 1 | 2020 | 1014 | 0.420 |
Why?
|
| Immunity, Cellular | 2 | 2016 | 1561 | 0.420 |
Why?
|
| Dyspnea | 1 | 2020 | 1351 | 0.410 |
Why?
|
| Animals, Genetically Modified | 10 | 2024 | 1563 | 0.410 |
Why?
|
| Herpesviridae | 1 | 2013 | 104 | 0.400 |
Why?
|
| Pneumococcal Infections | 1 | 2017 | 529 | 0.400 |
Why?
|
| Cryptococcus neoformans | 2 | 2009 | 121 | 0.380 |
Why?
|
| Polymerase Chain Reaction | 8 | 2023 | 6085 | 0.380 |
Why?
|
| Lymphoproliferative Disorders | 5 | 2007 | 529 | 0.380 |
Why?
|
| Virus Activation | 3 | 2004 | 322 | 0.380 |
Why?
|
| Streptococcus pneumoniae | 1 | 2017 | 764 | 0.380 |
Why?
|
| Meningitis, Cryptococcal | 2 | 2009 | 67 | 0.370 |
Why?
|
| Probiotics | 1 | 2015 | 383 | 0.370 |
Why?
|
| Hepacivirus | 6 | 2022 | 1342 | 0.370 |
Why?
|
| Risk Factors | 37 | 2018 | 74962 | 0.360 |
Why?
|
| Pandemics | 7 | 2021 | 8753 | 0.360 |
Why?
|
| Acquired Immunodeficiency Syndrome | 4 | 2016 | 2202 | 0.360 |
Why?
|
| Gram-Positive Bacterial Infections | 2 | 2003 | 342 | 0.360 |
Why?
|
| Kidney Diseases | 2 | 2017 | 2103 | 0.350 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2023 | 3666 | 0.350 |
Why?
|
| Aspergillosis | 6 | 2016 | 242 | 0.340 |
Why?
|
| Naphthoquinones | 4 | 2004 | 59 | 0.340 |
Why?
|
| Bacterial Infections | 2 | 2014 | 1397 | 0.340 |
Why?
|
| Antibodies, Neoplasm | 1 | 2011 | 283 | 0.340 |
Why?
|
| Immune System | 1 | 2015 | 801 | 0.330 |
Why?
|
| Killer Cells, Natural | 5 | 2012 | 2206 | 0.330 |
Why?
|
| Practice Guidelines as Topic | 7 | 2020 | 7453 | 0.330 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 9 | 2019 | 5713 | 0.320 |
Why?
|
| Influenza, Human | 2 | 2010 | 1539 | 0.310 |
Why?
|
| Bone Marrow Transplantation | 11 | 2015 | 2709 | 0.310 |
Why?
|
| Mycobacterium tuberculosis | 2 | 2019 | 1929 | 0.300 |
Why?
|
| Tuberculosis | 2 | 2019 | 2029 | 0.300 |
Why?
|
| Tissue Banks | 1 | 2008 | 184 | 0.290 |
Why?
|
| Quality Assurance, Health Care | 1 | 2018 | 2181 | 0.290 |
Why?
|
| Hepatitis B virus | 3 | 2022 | 530 | 0.290 |
Why?
|
| Chimerism | 1 | 2008 | 156 | 0.290 |
Why?
|
| Herpesvirus 4, Human | 2 | 2014 | 1082 | 0.290 |
Why?
|
| Mammary Glands, Animal | 3 | 2000 | 273 | 0.280 |
Why?
|
| Candidiasis | 5 | 2017 | 367 | 0.280 |
Why?
|
| Registries | 4 | 2018 | 8379 | 0.270 |
Why?
|
| Genome, Viral | 2 | 2010 | 673 | 0.270 |
Why?
|
| HIV Infections | 6 | 2022 | 17575 | 0.270 |
Why?
|
| Microbiological Techniques | 3 | 2019 | 97 | 0.270 |
Why?
|
| Drug Resistance, Viral | 1 | 2011 | 869 | 0.260 |
Why?
|
| Pseudomonas Infections | 2 | 2001 | 623 | 0.260 |
Why?
|
| Thymus Gland | 8 | 2009 | 1266 | 0.260 |
Why?
|
| Bioterrorism | 2 | 2003 | 144 | 0.260 |
Why?
|
| Candida | 6 | 2017 | 172 | 0.250 |
Why?
|
| Informed Consent | 3 | 2008 | 1010 | 0.240 |
Why?
|
| Antilymphocyte Serum | 6 | 2011 | 491 | 0.240 |
Why?
|
| Disseminated Intravascular Coagulation | 2 | 2004 | 187 | 0.240 |
Why?
|
| Weaning | 1 | 2005 | 103 | 0.240 |
Why?
|
| Anti-Bacterial Agents | 5 | 2019 | 7463 | 0.230 |
Why?
|
| Mycobacterium avium Complex | 1 | 2004 | 60 | 0.230 |
Why?
|
| Pilonidal Sinus | 1 | 2004 | 16 | 0.230 |
Why?
|
| Liver Failure | 1 | 2006 | 252 | 0.230 |
Why?
|
| Sus scrofa | 3 | 2014 | 430 | 0.230 |
Why?
|
| T-Lymphocytes | 10 | 2016 | 10267 | 0.230 |
Why?
|
| Hepatitis B | 3 | 2017 | 708 | 0.220 |
Why?
|
| Swine Diseases | 2 | 2001 | 61 | 0.220 |
Why?
|
| Homeostasis | 1 | 2015 | 3349 | 0.220 |
Why?
|
| Hepatitis C, Chronic | 3 | 2020 | 1031 | 0.220 |
Why?
|
| Neoplasms | 7 | 2022 | 22385 | 0.220 |
Why?
|
| Mycobacterium Infections | 1 | 2004 | 122 | 0.220 |
Why?
|
| Immunotherapy | 1 | 2019 | 4738 | 0.220 |
Why?
|
| Lung Transplantation | 3 | 2024 | 1309 | 0.220 |
Why?
|
| Smallpox | 1 | 2003 | 43 | 0.210 |
Why?
|
| Acyclovir | 3 | 2000 | 267 | 0.210 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2008 | 749 | 0.210 |
Why?
|
| Lymphocytic choriomeningitis virus | 3 | 2009 | 175 | 0.210 |
Why?
|
| Oxazolidinones | 1 | 2003 | 98 | 0.210 |
Why?
|
| Smallpox Vaccine | 1 | 2003 | 77 | 0.210 |
Why?
|
| Disease Susceptibility | 2 | 2020 | 1794 | 0.210 |
Why?
|
| Lung Diseases, Fungal | 1 | 2003 | 124 | 0.210 |
Why?
|
| Enterococcus faecium | 1 | 2003 | 101 | 0.210 |
Why?
|
| Recombination, Genetic | 2 | 2006 | 1526 | 0.200 |
Why?
|
| Foscarnet | 1 | 2002 | 36 | 0.200 |
Why?
|
| Fever | 4 | 2020 | 1620 | 0.200 |
Why?
|
| Transplantation Tolerance | 5 | 2014 | 633 | 0.200 |
Why?
|
| Severe Acute Respiratory Syndrome | 1 | 2003 | 136 | 0.200 |
Why?
|
| Amphotericin B | 6 | 2016 | 143 | 0.200 |
Why?
|
| Enterococcus | 1 | 2003 | 159 | 0.200 |
Why?
|
| Disease Outbreaks | 2 | 2009 | 1762 | 0.200 |
Why?
|
| Abscess | 3 | 2002 | 606 | 0.200 |
Why?
|
| Nephritis | 1 | 2003 | 147 | 0.200 |
Why?
|
| Islets of Langerhans Transplantation | 2 | 2017 | 748 | 0.190 |
Why?
|
| Acetamides | 1 | 2003 | 260 | 0.190 |
Why?
|
| Cytosine | 1 | 2003 | 213 | 0.190 |
Why?
|
| Fallopian Tube Diseases | 1 | 2001 | 60 | 0.190 |
Why?
|
| Listeriosis | 1 | 2002 | 147 | 0.180 |
Why?
|
| Vaccination | 3 | 2022 | 3431 | 0.180 |
Why?
|
| Lymphocyte Transfusion | 2 | 2016 | 232 | 0.180 |
Why?
|
| Papio hamadryas | 2 | 2018 | 32 | 0.180 |
Why?
|
| Leukemia, Myeloid | 1 | 2004 | 693 | 0.180 |
Why?
|
| Nucleic Acid Amplification Techniques | 2 | 2017 | 339 | 0.180 |
Why?
|
| Peptides, Cyclic | 2 | 2006 | 391 | 0.180 |
Why?
|
| Lymphocytes | 2 | 2008 | 2611 | 0.180 |
Why?
|
| Spleen | 1 | 2007 | 2296 | 0.180 |
Why?
|
| Fungi | 5 | 2009 | 345 | 0.180 |
Why?
|
| Mass Screening | 3 | 2011 | 5451 | 0.180 |
Why?
|
| Arenaviridae Infections | 3 | 2009 | 53 | 0.180 |
Why?
|
| Audiology | 1 | 2020 | 23 | 0.170 |
Why?
|
| Ovarian Diseases | 1 | 2001 | 137 | 0.170 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2020 | 220 | 0.170 |
Why?
|
| Lung Diseases | 1 | 2010 | 1925 | 0.170 |
Why?
|
| Communicable Disease Control | 3 | 2020 | 857 | 0.170 |
Why?
|
| Proteolipids | 2 | 1998 | 112 | 0.170 |
Why?
|
| Inflammation | 1 | 2019 | 10863 | 0.170 |
Why?
|
| Europe | 2 | 2023 | 3439 | 0.160 |
Why?
|
| Immune Tolerance | 8 | 2009 | 2324 | 0.160 |
Why?
|
| Risk | 6 | 2022 | 9636 | 0.160 |
Why?
|
| Glucocorticoids | 2 | 2023 | 2168 | 0.160 |
Why?
|
| Minority Groups | 1 | 2006 | 1215 | 0.160 |
Why?
|
| Caspases | 1 | 2002 | 881 | 0.160 |
Why?
|
| Pulmonary Surfactants | 2 | 1998 | 169 | 0.160 |
Why?
|
| Fungemia | 2 | 2009 | 57 | 0.150 |
Why?
|
| Echinocandins | 5 | 2016 | 53 | 0.150 |
Why?
|
| Exanthema | 1 | 2023 | 503 | 0.150 |
Why?
|
| Fungal Proteins | 2 | 2002 | 906 | 0.150 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2000 | 423 | 0.150 |
Why?
|
| Hydroxyestrones | 2 | 1995 | 17 | 0.150 |
Why?
|
| Environmental Health | 1 | 2000 | 295 | 0.150 |
Why?
|
| Immunization | 2 | 2021 | 1219 | 0.140 |
Why?
|
| Atovaquone | 4 | 2004 | 56 | 0.140 |
Why?
|
| Immunity, Humoral | 1 | 2022 | 611 | 0.140 |
Why?
|
| New York | 1 | 2020 | 884 | 0.140 |
Why?
|
| Wound Infection | 1 | 1999 | 243 | 0.140 |
Why?
|
| Trust | 1 | 2022 | 532 | 0.140 |
Why?
|
| Pentamidine | 3 | 2004 | 44 | 0.140 |
Why?
|
| Male | 51 | 2023 | 364902 | 0.140 |
Why?
|
| Antibodies, Monoclonal | 3 | 2011 | 9261 | 0.140 |
Why?
|
| Heart | 2 | 2020 | 4449 | 0.140 |
Why?
|
| Pneumonia, Bacterial | 1 | 1999 | 319 | 0.130 |
Why?
|
| Community-Acquired Infections | 1 | 2020 | 473 | 0.130 |
Why?
|
| United States | 16 | 2024 | 73150 | 0.130 |
Why?
|
| Pneumonia | 4 | 2002 | 2163 | 0.130 |
Why?
|
| Protozoan Infections | 1 | 1995 | 38 | 0.130 |
Why?
|
| Primates | 2 | 2014 | 521 | 0.130 |
Why?
|
| Virus Inactivation | 1 | 2015 | 19 | 0.130 |
Why?
|
| Human Experimentation | 1 | 1996 | 124 | 0.130 |
Why?
|
| Lymphocyte Depletion | 3 | 2016 | 605 | 0.130 |
Why?
|
| Diagnosis, Differential | 6 | 2020 | 13020 | 0.130 |
Why?
|
| Adult | 38 | 2021 | 223640 | 0.130 |
Why?
|
| Estradiol | 4 | 1995 | 1952 | 0.130 |
Why?
|
| Transplantation Conditioning | 5 | 2019 | 1600 | 0.130 |
Why?
|
| Societies, Medical | 5 | 2020 | 3960 | 0.130 |
Why?
|
| Risk Assessment | 7 | 2023 | 24318 | 0.120 |
Why?
|
| Thrombocytopenia | 1 | 2003 | 1180 | 0.120 |
Why?
|
| Monocytes | 1 | 2024 | 2595 | 0.120 |
Why?
|
| False Positive Reactions | 1 | 2017 | 962 | 0.120 |
Why?
|
| Research Report | 1 | 2018 | 369 | 0.120 |
Why?
|
| Blood Coagulation Factors | 1 | 2017 | 366 | 0.120 |
Why?
|
| Phytosterols | 1 | 1994 | 55 | 0.120 |
Why?
|
| Azoles | 3 | 2016 | 23 | 0.120 |
Why?
|
| Colitis, Ulcerative | 1 | 2006 | 1929 | 0.120 |
Why?
|
| HIV | 2 | 2017 | 1596 | 0.110 |
Why?
|
| Blood Donors | 1 | 2016 | 344 | 0.110 |
Why?
|
| Respiratory Insufficiency | 1 | 2023 | 1241 | 0.110 |
Why?
|
| Middle Aged | 35 | 2023 | 223491 | 0.110 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2017 | 3813 | 0.110 |
Why?
|
| Environmental Monitoring | 1 | 2000 | 1463 | 0.110 |
Why?
|
| Aspergillus fumigatus | 2 | 2008 | 158 | 0.110 |
Why?
|
| Indium Radioisotopes | 2 | 1991 | 116 | 0.110 |
Why?
|
| International Agencies | 1 | 2014 | 245 | 0.110 |
Why?
|
| Medical Tourism | 1 | 2014 | 51 | 0.110 |
Why?
|
| Aged | 27 | 2023 | 171562 | 0.110 |
Why?
|
| Treatment Outcome | 14 | 2022 | 65379 | 0.110 |
Why?
|
| Female | 53 | 2023 | 397089 | 0.110 |
Why?
|
| Immunoassay | 1 | 2017 | 745 | 0.110 |
Why?
|
| Transplantation Chimera | 4 | 2016 | 594 | 0.110 |
Why?
|
| Galactose | 1 | 2014 | 299 | 0.110 |
Why?
|
| Hepatitis B Antibodies | 1 | 2014 | 156 | 0.110 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2014 | 239 | 0.110 |
Why?
|
| Pneumococcal Vaccines | 1 | 2017 | 414 | 0.110 |
Why?
|
| Peptides | 2 | 2023 | 4353 | 0.110 |
Why?
|
| Motivation | 1 | 2023 | 2029 | 0.110 |
Why?
|
| Bile Acids and Salts | 1 | 1995 | 400 | 0.110 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 1993 | 94 | 0.110 |
Why?
|
| Diet, Fat-Restricted | 1 | 1995 | 329 | 0.110 |
Why?
|
| Disaccharides | 3 | 2004 | 170 | 0.100 |
Why?
|
| Fatal Outcome | 4 | 2017 | 1837 | 0.100 |
Why?
|
| Otolaryngology | 1 | 2020 | 701 | 0.100 |
Why?
|
| Trisaccharides | 2 | 2005 | 50 | 0.100 |
Why?
|
| Congresses as Topic | 1 | 2017 | 810 | 0.100 |
Why?
|
| Guanine | 1 | 2014 | 280 | 0.100 |
Why?
|
| Antibiotic Prophylaxis | 2 | 2013 | 640 | 0.100 |
Why?
|
| Postmenopause | 1 | 2001 | 2518 | 0.100 |
Why?
|
| Retrospective Studies | 7 | 2023 | 81801 | 0.100 |
Why?
|
| Case Management | 1 | 2014 | 276 | 0.100 |
Why?
|
| Lamivudine | 1 | 2014 | 367 | 0.100 |
Why?
|
| Bone Marrow Cells | 3 | 2015 | 2414 | 0.100 |
Why?
|
| Gene Targeting | 1 | 2015 | 841 | 0.100 |
Why?
|
| Kidney Failure, Chronic | 2 | 2019 | 2491 | 0.100 |
Why?
|
| Estriol | 2 | 1995 | 53 | 0.100 |
Why?
|
| Pseudomonas aeruginosa | 1 | 1999 | 1276 | 0.100 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2012 | 225 | 0.100 |
Why?
|
| Drug Interactions | 2 | 2010 | 1420 | 0.100 |
Why?
|
| Mycobacterium kansasii | 1 | 2011 | 8 | 0.100 |
Why?
|
| DNA Primers | 3 | 2012 | 2825 | 0.090 |
Why?
|
| Human T-lymphotropic virus 2 | 1 | 2011 | 10 | 0.090 |
Why?
|
| Injections, Intravenous | 4 | 2000 | 1379 | 0.090 |
Why?
|
| Cross Infection | 3 | 2009 | 1426 | 0.090 |
Why?
|
| Sputum | 1 | 1994 | 512 | 0.090 |
Why?
|
| Antibody Specificity | 2 | 2005 | 1065 | 0.090 |
Why?
|
| Antibodies, Bacterial | 1 | 2017 | 1478 | 0.090 |
Why?
|
| Reference Standards | 1 | 2014 | 1013 | 0.090 |
Why?
|
| Species Specificity | 4 | 2004 | 2417 | 0.090 |
Why?
|
| Pentetic Acid | 1 | 1991 | 209 | 0.090 |
Why?
|
| Antibodies | 4 | 2014 | 2425 | 0.090 |
Why?
|
| Women's Health | 1 | 2000 | 2078 | 0.090 |
Why?
|
| Molecular Sequence Data | 7 | 2015 | 17626 | 0.090 |
Why?
|
| Liver Abscess | 1 | 2011 | 81 | 0.090 |
Why?
|
| Comorbidity | 2 | 2020 | 10588 | 0.090 |
Why?
|
| Incidence | 5 | 2015 | 21544 | 0.090 |
Why?
|
| Antibodies, Viral | 1 | 2022 | 3211 | 0.090 |
Why?
|
| Human T-lymphotropic virus 1 | 1 | 2011 | 143 | 0.090 |
Why?
|
| Neutropenia | 2 | 2007 | 893 | 0.090 |
Why?
|
| Rats, Inbred Strains | 6 | 1991 | 2087 | 0.080 |
Why?
|
| Central Nervous System Fungal Infections | 1 | 2009 | 24 | 0.080 |
Why?
|
| Sarcoma, Kaposi | 1 | 2013 | 374 | 0.080 |
Why?
|
| Amino Acid Sequence | 6 | 2006 | 13423 | 0.080 |
Why?
|
| Life Cycle Stages | 1 | 2010 | 161 | 0.080 |
Why?
|
| Sepsis | 2 | 1999 | 2601 | 0.080 |
Why?
|
| Angioplasty, Balloon | 3 | 1988 | 592 | 0.080 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2019 | 1508 | 0.080 |
Why?
|
| Rats | 14 | 2001 | 23835 | 0.080 |
Why?
|
| Latent Tuberculosis | 1 | 2012 | 224 | 0.080 |
Why?
|
| Base Sequence | 4 | 2015 | 12422 | 0.080 |
Why?
|
| Reperfusion Injury | 1 | 2016 | 1033 | 0.080 |
Why?
|
| Respiration, Artificial | 1 | 2020 | 2721 | 0.080 |
Why?
|
| Thymectomy | 2 | 2002 | 200 | 0.080 |
Why?
|
| RNA, Messenger | 4 | 2008 | 12805 | 0.080 |
Why?
|
| Radiography | 1 | 2020 | 6993 | 0.080 |
Why?
|
| Hematologic Diseases | 1 | 2012 | 499 | 0.080 |
Why?
|
| GPI-Linked Proteins | 1 | 2010 | 473 | 0.080 |
Why?
|
| Disease Management | 1 | 2019 | 2537 | 0.080 |
Why?
|
| Antibodies, Heterophile | 2 | 1999 | 128 | 0.080 |
Why?
|
| Hematologic Neoplasms | 2 | 2019 | 1905 | 0.080 |
Why?
|
| Cell Line | 6 | 2015 | 15597 | 0.080 |
Why?
|
| Dapsone | 2 | 1998 | 55 | 0.080 |
Why?
|
| Breast | 2 | 1995 | 1975 | 0.080 |
Why?
|
| Health Care Costs | 2 | 2014 | 3267 | 0.080 |
Why?
|
| Burns | 1 | 1999 | 1893 | 0.070 |
Why?
|
| Adenine | 1 | 2014 | 993 | 0.070 |
Why?
|
| Clindamycin | 2 | 1998 | 138 | 0.070 |
Why?
|
| RNA, Ribosomal | 1 | 1989 | 227 | 0.070 |
Why?
|
| HIV-1 | 2 | 2003 | 6963 | 0.070 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2009 | 306 | 0.070 |
Why?
|
| Aneurysm, Infected | 1 | 2008 | 81 | 0.070 |
Why?
|
| Graft vs Host Disease | 2 | 2016 | 3044 | 0.070 |
Why?
|
| Antigens, Protozoan | 2 | 1989 | 315 | 0.070 |
Why?
|
| Genes, pol | 2 | 2015 | 52 | 0.070 |
Why?
|
| Extracellular Matrix Proteins | 1 | 1991 | 835 | 0.070 |
Why?
|
| Orthomyxoviridae Infections | 1 | 2009 | 255 | 0.070 |
Why?
|
| Cyclosporine | 4 | 2016 | 779 | 0.070 |
Why?
|
| Chemoprevention | 2 | 2012 | 326 | 0.070 |
Why?
|
| Disease Models, Animal | 10 | 2017 | 18362 | 0.070 |
Why?
|
| Phagocytosis | 3 | 2024 | 1530 | 0.070 |
Why?
|
| Fluconazole | 2 | 2009 | 156 | 0.070 |
Why?
|
| Coccidioides | 1 | 2006 | 17 | 0.070 |
Why?
|
| Gene Expression | 5 | 2024 | 7598 | 0.070 |
Why?
|
| Cost-Benefit Analysis | 3 | 2014 | 5538 | 0.070 |
Why?
|
| Th17 Cells | 1 | 2012 | 791 | 0.070 |
Why?
|
| Sulfamethoxazole | 2 | 2004 | 51 | 0.070 |
Why?
|
| B-Lymphocytes | 5 | 2012 | 4785 | 0.070 |
Why?
|
| Professional Misconduct | 1 | 2006 | 73 | 0.070 |
Why?
|
| Infectious Disease Medicine | 2 | 2016 | 49 | 0.070 |
Why?
|
| Analgesics, Opioid | 1 | 2022 | 3836 | 0.060 |
Why?
|
| Spinal Puncture | 1 | 2008 | 286 | 0.060 |
Why?
|
| Whole-Body Irradiation | 3 | 2016 | 435 | 0.060 |
Why?
|
| Coccidioidomycosis | 1 | 2006 | 36 | 0.060 |
Why?
|
| DNA, Complementary | 2 | 2000 | 1992 | 0.060 |
Why?
|
| Immunologic Memory | 1 | 2012 | 1374 | 0.060 |
Why?
|
| Trimethoprim | 2 | 2004 | 79 | 0.060 |
Why?
|
| Confusion | 1 | 2008 | 278 | 0.060 |
Why?
|
| Gene Products, env | 1 | 2006 | 250 | 0.060 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 1995 | 2846 | 0.060 |
Why?
|
| World Health Organization | 1 | 2012 | 1327 | 0.060 |
Why?
|
| Biological Assay | 1 | 2008 | 627 | 0.060 |
Why?
|
| Lymphocytic Choriomeningitis | 1 | 2006 | 140 | 0.060 |
Why?
|
| Puromycin Aminonucleoside | 1 | 1985 | 7 | 0.060 |
Why?
|
| Environmental Exposure | 1 | 2000 | 4528 | 0.060 |
Why?
|
| Puromycin | 1 | 1985 | 41 | 0.060 |
Why?
|
| Menstrual Cycle | 3 | 1995 | 545 | 0.060 |
Why?
|
| Proviruses | 3 | 2007 | 320 | 0.060 |
Why?
|
| Diagnostic Imaging | 1 | 2019 | 3541 | 0.060 |
Why?
|
| Clinical Trials as Topic | 3 | 2020 | 8051 | 0.060 |
Why?
|
| Basal Ganglia | 1 | 2008 | 555 | 0.060 |
Why?
|
| Ethics, Research | 1 | 2006 | 177 | 0.060 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 2000 | 2750 | 0.060 |
Why?
|
| Immunoglobulin G | 5 | 1998 | 4570 | 0.060 |
Why?
|
| Autoimmunity | 1 | 2012 | 1360 | 0.060 |
Why?
|
| Trichuriasis | 1 | 1984 | 24 | 0.060 |
Why?
|
| Cell Transplantation | 2 | 2004 | 475 | 0.060 |
Why?
|
| Aspergillus | 3 | 2010 | 95 | 0.060 |
Why?
|
| Metacarpus | 1 | 1984 | 37 | 0.060 |
Why?
|
| Intestinal Diseases, Parasitic | 1 | 1984 | 64 | 0.060 |
Why?
|
| Histocompatibility Antigens Class II | 2 | 1999 | 1438 | 0.060 |
Why?
|
| Drug Therapy, Combination | 4 | 2005 | 6318 | 0.060 |
Why?
|
| Lipids | 2 | 1994 | 3344 | 0.060 |
Why?
|
| Time Factors | 13 | 2010 | 40272 | 0.060 |
Why?
|
| Acute Disease | 2 | 2005 | 7242 | 0.060 |
Why?
|
| Antiretroviral Therapy, Highly Active | 2 | 2003 | 1903 | 0.060 |
Why?
|
| Lung | 5 | 2006 | 10089 | 0.050 |
Why?
|
| Radiography, Thoracic | 1 | 2010 | 1320 | 0.050 |
Why?
|
| Conserved Sequence | 1 | 2007 | 1163 | 0.050 |
Why?
|
| Open Reading Frames | 1 | 2007 | 812 | 0.050 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2002 | 1961 | 0.050 |
Why?
|
| Antitubercular Agents | 1 | 2012 | 1391 | 0.050 |
Why?
|
| Child | 10 | 2021 | 80891 | 0.050 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 1995 | 2044 | 0.050 |
Why?
|
| Survival Rate | 4 | 2017 | 12870 | 0.050 |
Why?
|
| Blood Cell Count | 1 | 2004 | 402 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2004 | 11854 | 0.050 |
Why?
|
| Aneurysm, Ruptured | 1 | 2008 | 462 | 0.050 |
Why?
|
| Death | 1 | 2007 | 683 | 0.050 |
Why?
|
| Evaluation Studies as Topic | 2 | 1996 | 1629 | 0.050 |
Why?
|
| HLA Antigens | 1 | 2008 | 1337 | 0.050 |
Why?
|
| Deoxycholic Acid | 2 | 2009 | 54 | 0.050 |
Why?
|
| Macrophages, Alveolar | 2 | 1998 | 415 | 0.050 |
Why?
|
| Risk-Taking | 1 | 2008 | 1026 | 0.050 |
Why?
|
| Bacteria | 1 | 1994 | 2221 | 0.050 |
Why?
|
| Indians, North American | 1 | 2006 | 354 | 0.050 |
Why?
|
| Skin Ulcer | 1 | 2004 | 130 | 0.050 |
Why?
|
| Forecasting | 3 | 2002 | 2948 | 0.050 |
Why?
|
| Triazoles | 2 | 2009 | 904 | 0.050 |
Why?
|
| Colonic Diseases | 1 | 1984 | 203 | 0.050 |
Why?
|
| Disclosure | 1 | 2008 | 754 | 0.050 |
Why?
|
| Inclusion Bodies, Viral | 1 | 2002 | 45 | 0.050 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2011 | 3731 | 0.050 |
Why?
|
| Kidney Glomerulus | 1 | 1985 | 569 | 0.050 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2024 | 325 | 0.050 |
Why?
|
| Gene Dosage | 2 | 2015 | 1221 | 0.050 |
Why?
|
| Caspases, Initiator | 1 | 2002 | 31 | 0.050 |
Why?
|
| Intestinal Perforation | 1 | 1984 | 253 | 0.050 |
Why?
|
| Nucleosides | 1 | 2002 | 131 | 0.050 |
Why?
|
| RNA-Directed DNA Polymerase | 1 | 2002 | 223 | 0.050 |
Why?
|
| Coronary Disease | 4 | 2009 | 5924 | 0.050 |
Why?
|
| Mammary Neoplasms, Experimental | 2 | 2000 | 506 | 0.050 |
Why?
|
| CD40 Ligand | 1 | 2004 | 524 | 0.050 |
Why?
|
| Mice | 12 | 2009 | 82017 | 0.050 |
Why?
|
| Platelet Count | 1 | 2004 | 784 | 0.050 |
Why?
|
| Models, Animal | 3 | 2005 | 2124 | 0.050 |
Why?
|
| Organophosphorus Compounds | 1 | 2003 | 207 | 0.050 |
Why?
|
| Pyrimidines | 3 | 2009 | 3048 | 0.050 |
Why?
|
| Candida glabrata | 1 | 2002 | 38 | 0.050 |
Why?
|
| Electronic Health Records | 2 | 2020 | 4875 | 0.050 |
Why?
|
| Vaccinia virus | 1 | 2003 | 330 | 0.050 |
Why?
|
| Quality Improvement | 1 | 2017 | 3858 | 0.050 |
Why?
|
| Dendritic Cells | 1 | 2012 | 2749 | 0.050 |
Why?
|
| Steroid 16-alpha-Hydroxylase | 3 | 1986 | 12 | 0.050 |
Why?
|
| Cytokines | 5 | 2024 | 7445 | 0.050 |
Why?
|
| Histocompatibility Testing | 4 | 2008 | 716 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2016 | 3440 | 0.050 |
Why?
|
| Mice, Inbred DBA | 1 | 2002 | 624 | 0.050 |
Why?
|
| Fibrinogen | 1 | 2004 | 891 | 0.050 |
Why?
|
| Immune Evasion | 1 | 2024 | 376 | 0.050 |
Why?
|
| RNA, Viral | 2 | 2007 | 2866 | 0.050 |
Why?
|
| Genes, Viral | 1 | 2002 | 655 | 0.050 |
Why?
|
| Gene Library | 2 | 2007 | 1061 | 0.050 |
Why?
|
| Treatment Failure | 2 | 2004 | 2663 | 0.050 |
Why?
|
| Naloxone | 2 | 1983 | 372 | 0.050 |
Why?
|
| Mandatory Testing | 1 | 2020 | 23 | 0.040 |
Why?
|
| Membrane Glycoproteins | 2 | 2010 | 3712 | 0.040 |
Why?
|
| Administration, Oral | 4 | 2000 | 4039 | 0.040 |
Why?
|
| Interleukin-18 | 1 | 2002 | 251 | 0.040 |
Why?
|
| Intestinal Obstruction | 1 | 1984 | 435 | 0.040 |
Why?
|
| Body Burden | 1 | 2000 | 158 | 0.040 |
Why?
|
| Creatinine | 3 | 2014 | 1915 | 0.040 |
Why?
|
| Pulmonary Surfactant-Associated Proteins | 2 | 1998 | 18 | 0.040 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2000 | 108 | 0.040 |
Why?
|
| Listeria monocytogenes | 1 | 2002 | 246 | 0.040 |
Why?
|
| Pulmonary Surfactant-Associated Protein A | 2 | 1998 | 32 | 0.040 |
Why?
|
| Reference Values | 3 | 1997 | 4941 | 0.040 |
Why?
|
| Receptors, CCR5 | 1 | 2002 | 491 | 0.040 |
Why?
|
| Breast Neoplasms | 4 | 2000 | 21162 | 0.040 |
Why?
|
| Estrogens | 1 | 1986 | 1534 | 0.040 |
Why?
|
| Drugs, Investigational | 1 | 2002 | 213 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 6 | 2009 | 22355 | 0.040 |
Why?
|
| Social Control, Formal | 2 | 1998 | 107 | 0.040 |
Why?
|
| Antigens, CD | 1 | 2010 | 4031 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2006 | 1855 | 0.040 |
Why?
|
| Ovulation | 1 | 1980 | 181 | 0.040 |
Why?
|
| Interleukin-12 | 1 | 2002 | 577 | 0.040 |
Why?
|
| Prevalence | 2 | 2014 | 15872 | 0.040 |
Why?
|
| Leukopenia | 1 | 2000 | 212 | 0.040 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2002 | 622 | 0.040 |
Why?
|
| Hepatitis B, Chronic | 1 | 2003 | 413 | 0.040 |
Why?
|
| Antigen Presentation | 1 | 2024 | 1251 | 0.040 |
Why?
|
| Drug Resistance, Microbial | 1 | 2002 | 830 | 0.040 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2012 | 3112 | 0.040 |
Why?
|
| Galactosides | 1 | 1998 | 54 | 0.040 |
Why?
|
| Prognosis | 4 | 2014 | 30022 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2011 | 15455 | 0.040 |
Why?
|
| Viremia | 2 | 1999 | 725 | 0.040 |
Why?
|
| Empathy | 1 | 2003 | 476 | 0.040 |
Why?
|
| Trimetrexate | 1 | 1998 | 15 | 0.040 |
Why?
|
| Epithelial Cells | 3 | 2015 | 3695 | 0.040 |
Why?
|
| Travel | 1 | 2005 | 800 | 0.040 |
Why?
|
| Drug Combinations | 2 | 2019 | 2079 | 0.040 |
Why?
|
| Fungal Vaccines | 1 | 1998 | 7 | 0.040 |
Why?
|
| Eflornithine | 1 | 1998 | 31 | 0.040 |
Why?
|
| Endocarditis, Bacterial | 1 | 1983 | 436 | 0.040 |
Why?
|
| Prospective Studies | 5 | 2017 | 54920 | 0.040 |
Why?
|
| Genes, gag | 1 | 1998 | 58 | 0.040 |
Why?
|
| Intracranial Aneurysm | 1 | 2008 | 1293 | 0.040 |
Why?
|
| Extracorporeal Circulation | 1 | 1998 | 181 | 0.040 |
Why?
|
| Safety | 2 | 2000 | 1159 | 0.040 |
Why?
|
| Pyrimethamine | 1 | 1998 | 94 | 0.040 |
Why?
|
| Constipation | 1 | 1983 | 570 | 0.040 |
Why?
|
| Disease | 1 | 2003 | 673 | 0.040 |
Why?
|
| Education, Medical, Graduate | 1 | 2010 | 2412 | 0.040 |
Why?
|
| Interferon-gamma | 2 | 2005 | 3164 | 0.040 |
Why?
|
| Liver Cirrhosis | 1 | 2008 | 1959 | 0.040 |
Why?
|
| Fibula | 1 | 1980 | 270 | 0.040 |
Why?
|
| Pyrrolidines | 1 | 2019 | 340 | 0.040 |
Why?
|
| Lymphocyte Activation | 2 | 2006 | 5496 | 0.040 |
Why?
|
| Quinoxalines | 1 | 2019 | 297 | 0.040 |
Why?
|
| Peritonitis | 1 | 1999 | 368 | 0.040 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2000 | 631 | 0.030 |
Why?
|
| Alcoholism | 1 | 2008 | 1982 | 0.030 |
Why?
|
| Adolescent | 8 | 2009 | 89184 | 0.030 |
Why?
|
| Gene Deletion | 1 | 2005 | 2673 | 0.030 |
Why?
|
| Macrolides | 1 | 1998 | 205 | 0.030 |
Why?
|
| Salvage Therapy | 1 | 2003 | 1277 | 0.030 |
Why?
|
| United States Food and Drug Administration | 2 | 2023 | 1672 | 0.030 |
Why?
|
| Receptors, Virus | 1 | 2000 | 648 | 0.030 |
Why?
|
| Puberty | 1 | 1980 | 502 | 0.030 |
Why?
|
| Cloning, Molecular | 2 | 2002 | 4168 | 0.030 |
Why?
|
| Rabbits | 1 | 2023 | 4781 | 0.030 |
Why?
|
| MicroRNAs | 1 | 2012 | 3804 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2012 | 9510 | 0.030 |
Why?
|
| Tibial Fractures | 1 | 1980 | 276 | 0.030 |
Why?
|
| Voice Disorders | 1 | 2020 | 286 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2024 | 2146 | 0.030 |
Why?
|
| Aneurysm | 1 | 1980 | 343 | 0.030 |
Why?
|
| Curriculum | 1 | 2010 | 3776 | 0.030 |
Why?
|
| Epithelium | 2 | 1995 | 1609 | 0.030 |
Why?
|
| Hydroxylation | 2 | 1986 | 139 | 0.030 |
Why?
|
| Coronary Vessels | 1 | 1988 | 3125 | 0.030 |
Why?
|
| Anti-HIV Agents | 2 | 2003 | 4571 | 0.030 |
Why?
|
| Adenoviridae | 1 | 2000 | 1096 | 0.030 |
Why?
|
| Leukocyte Count | 4 | 2004 | 1605 | 0.030 |
Why?
|
| Estrogens, Catechol | 1 | 1995 | 25 | 0.030 |
Why?
|
| Cholic Acids | 1 | 1995 | 39 | 0.030 |
Why?
|
| Lithocholic Acid | 1 | 1995 | 23 | 0.030 |
Why?
|
| HLA-DR Antigens | 1 | 1997 | 607 | 0.030 |
Why?
|
| Cholic Acid | 1 | 1995 | 31 | 0.030 |
Why?
|
| 9,10-Dimethyl-1,2-benzanthracene | 1 | 1995 | 58 | 0.030 |
Why?
|
| Blood Component Removal | 1 | 1997 | 132 | 0.030 |
Why?
|
| Chenodeoxycholic Acid | 1 | 1995 | 34 | 0.030 |
Why?
|
| Ursodeoxycholic Acid | 1 | 1995 | 81 | 0.030 |
Why?
|
| Causality | 1 | 2002 | 1255 | 0.030 |
Why?
|
| Recurrence | 4 | 2005 | 8506 | 0.030 |
Why?
|
| Physarum polycephalum | 1 | 1994 | 2 | 0.030 |
Why?
|
| Internet | 1 | 2007 | 3107 | 0.030 |
Why?
|
| Fibrinolytic Agents | 1 | 2005 | 2074 | 0.030 |
Why?
|
| Databases, Factual | 2 | 2007 | 8075 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 3 | 2009 | 6234 | 0.030 |
Why?
|
| DNA | 1 | 1989 | 7211 | 0.030 |
Why?
|
| Hepatocytes | 1 | 2002 | 1245 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2002 | 4588 | 0.030 |
Why?
|
| Chromatography, Gas | 1 | 1994 | 150 | 0.030 |
Why?
|
| Leg | 1 | 1980 | 1088 | 0.030 |
Why?
|
| Child, Preschool | 5 | 2020 | 42650 | 0.030 |
Why?
|
| Research | 2 | 2017 | 1981 | 0.030 |
Why?
|
| Recombinant Proteins | 2 | 2002 | 6510 | 0.030 |
Why?
|
| Biopsy | 3 | 2008 | 6808 | 0.030 |
Why?
|
| Waiting Lists | 1 | 2019 | 780 | 0.030 |
Why?
|
| Cell Adhesion | 3 | 1994 | 3102 | 0.030 |
Why?
|
| Lipopolysaccharides | 1 | 2002 | 2215 | 0.030 |
Why?
|
| Mice, SCID | 2 | 2004 | 2632 | 0.030 |
Why?
|
| Mycobacteriaceae | 1 | 1994 | 5 | 0.030 |
Why?
|
| Patient Selection | 2 | 2022 | 4266 | 0.030 |
Why?
|
| Blotting, Northern | 1 | 1996 | 1553 | 0.030 |
Why?
|
| Deglutition Disorders | 1 | 2020 | 641 | 0.030 |
Why?
|
| Transgenes | 1 | 1997 | 1015 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 2 | 1996 | 8199 | 0.030 |
Why?
|
| Benzimidazoles | 1 | 2019 | 864 | 0.030 |
Why?
|
| Gene Transfer Techniques | 1 | 1999 | 1209 | 0.030 |
Why?
|
| Health Policy | 1 | 2006 | 2698 | 0.030 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 1994 | 352 | 0.030 |
Why?
|
| Teniposide | 1 | 1993 | 11 | 0.030 |
Why?
|
| Fleroxacin | 1 | 1993 | 13 | 0.030 |
Why?
|
| Hepatitis B Core Antigens | 1 | 2014 | 90 | 0.030 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2004 | 1399 | 0.030 |
Why?
|
| Bone Marrow | 1 | 2004 | 2929 | 0.030 |
Why?
|
| Serial Passage | 1 | 1993 | 23 | 0.030 |
Why?
|
| Carcinogens | 1 | 1995 | 455 | 0.030 |
Why?
|
| Organ Culture Techniques | 1 | 1995 | 796 | 0.030 |
Why?
|
| Cells, Cultured | 4 | 2004 | 19022 | 0.030 |
Why?
|
| Aspirin | 1 | 2005 | 3135 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2007 | 7599 | 0.030 |
Why?
|
| Interleukin-2 | 1 | 2000 | 1894 | 0.030 |
Why?
|
| Mice, Inbred Strains | 1 | 1995 | 1769 | 0.030 |
Why?
|
| Patient Admission | 1 | 2020 | 1367 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2003 | 2598 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2000 | 6132 | 0.030 |
Why?
|
| Transfection | 1 | 2000 | 5764 | 0.030 |
Why?
|
| Vaginal Smears | 1 | 1995 | 505 | 0.030 |
Why?
|
| Young Adult | 4 | 2019 | 60049 | 0.030 |
Why?
|
| Sinusitis | 1 | 2002 | 995 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 1995 | 1705 | 0.030 |
Why?
|
| Leukapheresis | 1 | 2012 | 150 | 0.030 |
Why?
|
| Immunotoxins | 1 | 2012 | 175 | 0.030 |
Why?
|
| Macaca fascicularis | 1 | 2014 | 913 | 0.020 |
Why?
|
| Developing Countries | 1 | 2005 | 2903 | 0.020 |
Why?
|
| Decision Trees | 1 | 2014 | 509 | 0.020 |
Why?
|
| Reproducibility of Results | 2 | 2003 | 20224 | 0.020 |
Why?
|
| Indium | 1 | 1991 | 47 | 0.020 |
Why?
|
| Haplorhini | 2 | 1997 | 524 | 0.020 |
Why?
|
| Technetium Tc 99m Aggregated Albumin | 1 | 1991 | 66 | 0.020 |
Why?
|
| Bone Neoplasms | 1 | 1984 | 2565 | 0.020 |
Why?
|
| Premenopause | 1 | 1995 | 1039 | 0.020 |
Why?
|
| European Union | 1 | 2012 | 157 | 0.020 |
Why?
|
| Body Weight | 2 | 1989 | 4629 | 0.020 |
Why?
|
| Health Education | 1 | 1998 | 1057 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1994 | 1539 | 0.020 |
Why?
|
| Smoking | 2 | 1989 | 9111 | 0.020 |
Why?
|
| Thrombosis | 1 | 2005 | 2955 | 0.020 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2014 | 1133 | 0.020 |
Why?
|
| Hospitalization | 2 | 2010 | 10844 | 0.020 |
Why?
|
| Frontal Lobe | 1 | 1997 | 1428 | 0.020 |
Why?
|
| Gallium Radioisotopes | 1 | 1991 | 195 | 0.020 |
Why?
|
| Markov Chains | 1 | 2014 | 977 | 0.020 |
Why?
|
| Cryptococcus | 1 | 2010 | 28 | 0.020 |
Why?
|
| Laminin | 1 | 1991 | 406 | 0.020 |
Why?
|
| Receptors, Opioid | 2 | 1983 | 145 | 0.020 |
Why?
|
| Health Planning Guidelines | 1 | 2010 | 153 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2019 | 1980 | 0.020 |
Why?
|
| Liver | 2 | 2006 | 7574 | 0.020 |
Why?
|
| Temporal Lobe | 1 | 1997 | 1728 | 0.020 |
Why?
|
| Follow-Up Studies | 6 | 2019 | 39407 | 0.020 |
Why?
|
| Fluorescence | 1 | 1991 | 759 | 0.020 |
Why?
|
| Specimen Handling | 1 | 1994 | 708 | 0.020 |
Why?
|
| Blood Coagulation | 2 | 2009 | 1161 | 0.020 |
Why?
|
| Mucorales | 1 | 2009 | 35 | 0.020 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 1989 | 205 | 0.020 |
Why?
|
| Aged, 80 and over | 4 | 2009 | 59686 | 0.020 |
Why?
|
| Hemodynamics | 1 | 2019 | 4199 | 0.020 |
Why?
|
| Lung Diseases, Parasitic | 1 | 1988 | 14 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2020 | 3857 | 0.020 |
Why?
|
| Biomedical Research | 1 | 2024 | 3464 | 0.020 |
Why?
|
| Major Histocompatibility Complex | 2 | 2004 | 877 | 0.020 |
Why?
|
| Immunologic Tests | 1 | 1989 | 104 | 0.020 |
Why?
|
| Fibronectins | 1 | 1991 | 724 | 0.020 |
Why?
|
| Killer Cells, Lymphokine-Activated | 1 | 2007 | 42 | 0.020 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 1989 | 360 | 0.020 |
Why?
|
| Combined Modality Therapy | 3 | 2008 | 8562 | 0.020 |
Why?
|
| Polyethylene Terephthalates | 1 | 1988 | 112 | 0.020 |
Why?
|
| Antibodies, Protozoan | 1 | 1989 | 251 | 0.020 |
Why?
|
| Complement Activation | 1 | 2009 | 447 | 0.020 |
Why?
|
| Drug Evaluation | 1 | 1989 | 642 | 0.020 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 1 | 2008 | 165 | 0.020 |
Why?
|
| Paranasal Sinus Diseases | 1 | 2008 | 121 | 0.020 |
Why?
|
| Critical Illness | 1 | 2020 | 2755 | 0.020 |
Why?
|
| Massachusetts | 1 | 2020 | 8902 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1989 | 1305 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 1995 | 2247 | 0.020 |
Why?
|
| Disease Notification | 1 | 2007 | 95 | 0.020 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2014 | 1735 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2008 | 36849 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 1998 | 4775 | 0.020 |
Why?
|
| Pneumonia, Pneumococcal | 1 | 1988 | 134 | 0.020 |
Why?
|
| Phylogeny | 1 | 1994 | 2843 | 0.020 |
Why?
|
| Temporal Arteries | 1 | 2008 | 155 | 0.020 |
Why?
|
| Infarction | 1 | 2008 | 247 | 0.020 |
Why?
|
| Renal Circulation | 1 | 2007 | 291 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2010 | 20765 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2020 | 3801 | 0.020 |
Why?
|
| Cross Reactions | 1 | 1989 | 828 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 1991 | 1998 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2000 | 11120 | 0.020 |
Why?
|
| Gene Knockout Techniques | 1 | 2009 | 808 | 0.020 |
Why?
|
| Proteinuria | 1 | 2009 | 613 | 0.020 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 1989 | 761 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2009 | 1755 | 0.020 |
Why?
|
| Menopause | 2 | 1986 | 1653 | 0.020 |
Why?
|
| Lipopeptides | 1 | 2006 | 71 | 0.020 |
Why?
|
| Pregnenolone | 1 | 1986 | 27 | 0.020 |
Why?
|
| Dexamethasone | 2 | 1991 | 1965 | 0.020 |
Why?
|
| Granzymes | 1 | 2008 | 278 | 0.020 |
Why?
|
| Mammary Tumor Virus, Mouse | 1 | 1986 | 41 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2020 | 5367 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2015 | 4291 | 0.020 |
Why?
|
| Los Angeles | 1 | 2006 | 245 | 0.020 |
Why?
|
| Apoptosis | 1 | 2002 | 9516 | 0.020 |
Why?
|
| Haplotypes | 2 | 2004 | 2724 | 0.020 |
Why?
|
| Diagnosis-Related Groups | 1 | 2007 | 448 | 0.020 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2002 | 3620 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2019 | 8731 | 0.020 |
Why?
|
| Chromosomes | 1 | 1989 | 579 | 0.020 |
Why?
|
| Myocardium | 3 | 2004 | 4788 | 0.020 |
Why?
|
| Immunoblotting | 1 | 1989 | 1647 | 0.020 |
Why?
|
| Pan troglodytes | 1 | 1986 | 224 | 0.020 |
Why?
|
| Dihydrotestosterone | 1 | 1986 | 195 | 0.020 |
Why?
|
| North America | 1 | 2009 | 1290 | 0.020 |
Why?
|
| Resource Allocation | 1 | 2007 | 354 | 0.020 |
Why?
|
| Ethics Committees, Research | 1 | 2006 | 196 | 0.020 |
Why?
|
| Pediatrics | 1 | 2020 | 3624 | 0.020 |
Why?
|
| Glucosamine | 1 | 1985 | 128 | 0.010 |
Why?
|
| Receptors, Complement | 1 | 2005 | 254 | 0.010 |
Why?
|
| Serum Albumin, Bovine | 1 | 2005 | 320 | 0.010 |
Why?
|
| Optic Nerve | 1 | 2008 | 571 | 0.010 |
Why?
|
| Mice, Inbred C3H | 1 | 1986 | 915 | 0.010 |
Why?
|
| Public Health | 1 | 1998 | 2682 | 0.010 |
Why?
|
| Blotting, Western | 2 | 1989 | 5037 | 0.010 |
Why?
|
| Coronary Circulation | 2 | 2007 | 1617 | 0.010 |
Why?
|
| Giant Cell Arteritis | 1 | 2008 | 307 | 0.010 |
Why?
|
| Membrane Lipids | 1 | 1985 | 251 | 0.010 |
Why?
|
| Antigens | 1 | 2009 | 1443 | 0.010 |
Why?
|
| Cohort Studies | 2 | 2014 | 41795 | 0.010 |
Why?
|
| Drug Resistance, Fungal | 1 | 2003 | 77 | 0.010 |
Why?
|
| Leucine | 1 | 1985 | 548 | 0.010 |
Why?
|
| Magnesium Chloride | 1 | 2002 | 30 | 0.010 |
Why?
|
| Disease Progression | 1 | 2020 | 13646 | 0.010 |
Why?
|
| Manganese Compounds | 1 | 2002 | 25 | 0.010 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 1985 | 946 | 0.010 |
Why?
|
| Ribonuclease H | 1 | 2002 | 52 | 0.010 |
Why?
|
| Immunoglobulin M | 2 | 1998 | 1528 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 2006 | 2559 | 0.010 |
Why?
|
| New England | 1 | 2006 | 1058 | 0.010 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2003 | 412 | 0.010 |
Why?
|
| Cricetinae | 1 | 2006 | 2423 | 0.010 |
Why?
|
| Microcirculation | 1 | 2007 | 1282 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 15939 | 0.010 |
Why?
|
| Dementia | 1 | 1997 | 2729 | 0.010 |
Why?
|
| Hematocrit | 1 | 2003 | 625 | 0.010 |
Why?
|
| Biotransformation | 1 | 1982 | 166 | 0.010 |
Why?
|
| Consensus | 1 | 2012 | 3212 | 0.010 |
Why?
|
| Primary Prevention | 1 | 1989 | 1187 | 0.010 |
Why?
|
| Interleukin-4 | 1 | 2005 | 1157 | 0.010 |
Why?
|
| Klebsiella Infections | 1 | 1983 | 146 | 0.010 |
Why?
|
| Progesterone | 1 | 1986 | 751 | 0.010 |
Why?
|
| Multicenter Studies as Topic | 1 | 2006 | 1727 | 0.010 |
Why?
|
| Vision Disorders | 1 | 2008 | 1093 | 0.010 |
Why?
|
| Sodium Chloride | 1 | 2002 | 584 | 0.010 |
Why?
|
| Brain | 4 | 2008 | 27454 | 0.010 |
Why?
|
| Palatine Tonsil | 1 | 2001 | 193 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2004 | 2475 | 0.010 |
Why?
|
| Homeodomain Proteins | 1 | 2009 | 2429 | 0.010 |
Why?
|
| Headache | 1 | 2008 | 1262 | 0.010 |
Why?
|
| Mice, Inbred NOD | 1 | 2004 | 1839 | 0.010 |
Why?
|
| Adenosine | 1 | 1985 | 817 | 0.010 |
Why?
|
| Chlorides | 1 | 2002 | 663 | 0.010 |
Why?
|
| Equipment Design | 1 | 1988 | 3529 | 0.010 |
Why?
|
| DNA-Directed DNA Polymerase | 1 | 2002 | 481 | 0.010 |
Why?
|
| Fractures, Closed | 1 | 1980 | 88 | 0.010 |
Why?
|
| Canada | 1 | 2005 | 2139 | 0.010 |
Why?
|
| Drug Approval | 1 | 2006 | 818 | 0.010 |
Why?
|
| Dancing | 1 | 1980 | 105 | 0.010 |
Why?
|
| Immunosorbent Techniques | 1 | 1998 | 174 | 0.010 |
Why?
|
| Macrophages | 1 | 1994 | 5796 | 0.010 |
Why?
|
| Placebos | 1 | 1983 | 1668 | 0.010 |
Why?
|
| Molecular Structure | 1 | 2002 | 1884 | 0.010 |
Why?
|
| Journalism, Medical | 1 | 1998 | 73 | 0.010 |
Why?
|
| Streptococcal Infections | 1 | 1983 | 619 | 0.010 |
Why?
|
| Hypertension | 2 | 1989 | 8615 | 0.010 |
Why?
|
| Animal Experimentation | 1 | 1998 | 46 | 0.010 |
Why?
|
| Ethics | 1 | 1998 | 93 | 0.010 |
Why?
|
| Hybrid Cells | 1 | 1997 | 421 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2004 | 2524 | 0.010 |
Why?
|
| Endorphins | 1 | 1977 | 73 | 0.010 |
Why?
|
| Edetic Acid | 1 | 1998 | 278 | 0.010 |
Why?
|
| Hemoperfusion | 1 | 1997 | 13 | 0.010 |
Why?
|
| Chromatography, Affinity | 1 | 1998 | 525 | 0.010 |
Why?
|
| Hemoglobins | 1 | 2003 | 1532 | 0.010 |
Why?
|
| Hydrolases | 1 | 1998 | 146 | 0.010 |
Why?
|
| Enkephalins | 1 | 1977 | 139 | 0.010 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 1997 | 510 | 0.010 |
Why?
|
| Guideline Adherence | 1 | 2007 | 2240 | 0.010 |
Why?
|
| Concanavalin A | 1 | 1997 | 190 | 0.010 |
Why?
|
| Splenectomy | 1 | 1998 | 392 | 0.010 |
Why?
|
| Discriminant Analysis | 1 | 1997 | 222 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2007 | 6541 | 0.010 |
Why?
|
| Thinness | 1 | 1980 | 483 | 0.010 |
Why?
|
| Amenorrhea | 1 | 1980 | 484 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 2001 | 2176 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2009 | 10117 | 0.010 |
Why?
|
| Ureter | 1 | 1999 | 370 | 0.010 |
Why?
|
| Colon | 1 | 1984 | 1805 | 0.010 |
Why?
|
| Infant | 2 | 2009 | 36510 | 0.010 |
Why?
|
| ABO Blood-Group System | 1 | 1998 | 381 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 2001 | 1866 | 0.010 |
Why?
|
| Oxidation-Reduction | 1 | 1982 | 2225 | 0.010 |
Why?
|
| Brain Damage, Chronic | 1 | 1976 | 267 | 0.010 |
Why?
|
| Transcription Factors | 1 | 1995 | 12166 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 1991 | 14737 | 0.010 |
Why?
|
| Intelligence Tests | 1 | 1976 | 505 | 0.010 |
Why?
|
| Alzheimer Disease | 1 | 1997 | 8747 | 0.010 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2000 | 669 | 0.010 |
Why?
|
| Lymphoid Tissue | 1 | 1997 | 446 | 0.010 |
Why?
|
| Candida albicans | 1 | 1998 | 375 | 0.010 |
Why?
|
| Testosterone | 1 | 1986 | 2493 | 0.010 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 1998 | 1355 | 0.010 |
Why?
|
| Transduction, Genetic | 1 | 1997 | 902 | 0.010 |
Why?
|
| Antigens, Viral | 1 | 1998 | 992 | 0.010 |
Why?
|
| Isoantigens | 1 | 1997 | 563 | 0.010 |
Why?
|
| Angiography | 1 | 1980 | 1598 | 0.010 |
Why?
|
| Transplantation, Autologous | 1 | 1999 | 2127 | 0.010 |
Why?
|
| Kinetics | 1 | 1982 | 6333 | 0.010 |
Why?
|
| Logistic Models | 1 | 2009 | 13323 | 0.010 |
Why?
|
| Genetic Testing | 1 | 2007 | 3587 | 0.010 |
Why?
|
| Random Allocation | 2 | 1989 | 2397 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2004 | 5900 | 0.010 |
Why?
|
| Staphylococcal Infections | 1 | 1983 | 1398 | 0.010 |
Why?
|
| Isoantibodies | 1 | 1997 | 682 | 0.010 |
Why?
|
| Skin Transplantation | 1 | 1999 | 1097 | 0.010 |
Why?
|
| Antigen-Presenting Cells | 1 | 1997 | 962 | 0.010 |
Why?
|
| Sodium | 2 | 1989 | 1594 | 0.010 |
Why?
|
| Uncertainty | 1 | 1998 | 759 | 0.010 |
Why?
|
| Diet | 1 | 1991 | 8090 | 0.010 |
Why?
|
| Quality of Health Care | 1 | 2007 | 4339 | 0.010 |
Why?
|
| Epitopes | 1 | 1999 | 2525 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2004 | 9562 | 0.010 |
Why?
|
| Fluorometry | 1 | 1991 | 99 | 0.010 |
Why?
|
| Fluorescein-5-isothiocyanate | 1 | 1991 | 222 | 0.010 |
Why?
|
| Guidelines as Topic | 1 | 1998 | 1397 | 0.010 |
Why?
|
| Glycoproteins | 1 | 1998 | 2204 | 0.010 |
Why?
|
| Mice, Nude | 1 | 1997 | 3632 | 0.010 |
Why?
|
| Interleukin-1 | 1 | 1994 | 1251 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2005 | 14481 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2000 | 6856 | 0.010 |
Why?
|
| Fetus | 1 | 1997 | 1883 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2001 | 3471 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2009 | 26411 | 0.000 |
Why?
|
| Age Factors | 1 | 1986 | 18471 | 0.000 |
Why?
|
| Chronic Disease | 1 | 1983 | 9379 | 0.000 |
Why?
|
| Natriuresis | 1 | 1987 | 105 | 0.000 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 1997 | 6034 | 0.000 |
Why?
|
| Alcohol Drinking | 2 | 1989 | 4049 | 0.000 |
Why?
|
| Potassium | 1 | 1989 | 1318 | 0.000 |
Why?
|
| Antigens, Surface | 1 | 1989 | 1616 | 0.000 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 1997 | 4411 | 0.000 |
Why?
|
| Interleukin-6 | 1 | 1994 | 3230 | 0.000 |
Why?
|
| Diet, Reducing | 1 | 1987 | 487 | 0.000 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1994 | 4357 | 0.000 |
Why?
|
| Trachea | 1 | 1988 | 1095 | 0.000 |
Why?
|
| Monitoring, Physiologic | 1 | 1989 | 1795 | 0.000 |
Why?
|
| Cardiac Surgical Procedures | 1 | 1976 | 3681 | 0.000 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 1962 | 619 | 0.000 |
Why?
|
| Pituitary Gland | 1 | 1962 | 634 | 0.000 |
Why?
|
| Cell Differentiation | 1 | 1997 | 11668 | 0.000 |
Why?
|
| Exercise Test | 1 | 1987 | 2186 | 0.000 |
Why?
|
| Allyl Compounds | 1 | 1977 | 22 | 0.000 |
Why?
|
| Life Style | 1 | 1989 | 3929 | 0.000 |
Why?
|
| Tachyphylaxis | 1 | 1977 | 54 | 0.000 |
Why?
|
| Antihypertensive Agents | 1 | 1987 | 2027 | 0.000 |
Why?
|
| Algorithms | 1 | 1997 | 14154 | 0.000 |
Why?
|
| Guinea Pigs | 1 | 1977 | 1309 | 0.000 |
Why?
|
| Coronary Angiography | 1 | 1987 | 4537 | 0.000 |
Why?
|
| Muscle, Smooth | 1 | 1977 | 930 | 0.000 |
Why?
|
| Exercise | 1 | 1989 | 5946 | 0.000 |
Why?
|
| Muscle Contraction | 1 | 1977 | 1208 | 0.000 |
Why?
|
| Heart Valve Prosthesis | 1 | 1976 | 1468 | 0.000 |
Why?
|
| Coronary Artery Bypass | 1 | 1976 | 2194 | 0.000 |
Why?
|
| Suicide | 1 | 1976 | 1607 | 0.000 |
Why?
|
| Delirium | 1 | 1976 | 1695 | 0.000 |
Why?
|